Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis.
Conclusion: Commercially insured patients with PsA initiating apremilast had adherence similar to those initiating biologics but lower total healthcare costs.
PMID: 31081676 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
More News: Arthritis | General Medicine | Healthcare Costs | Insurance | Psoriatic Arthritis | Rheumatology